Article
Hematology
Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson
Summary: Rpn10 is highly expressed in MM cells and its inhibition can decrease MM cell viability by triggering protein accumulation, cell cycle arrest, and apoptosis. Additionally, inhibiting Rpn10 can increase autophagy, antigen presentation, and activate CD4(+) T and natural killer cells.
Article
Oncology
Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan, Ye Yang
Summary: The study found that AHSA1 expression was increased in multiple myeloma samples, which was significantly associated with disease relapse and poor prognosis. Additionally, AHSA1 played a role in promoting MM cell proliferation and proteasome inhibitor (PI) resistance. Bufalin and KU-177, as selective inhibitors of AHSA1, may be promising targets for treating MM cell proliferation and proteasome inhibitor resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ying Yang, Zhuogang Liu, Hongtao Wang, Guojun Zhang
Summary: Human leukocyte antigen-E (HLA-E) expression is different between multiple myeloma (MM) and normal plasma cells, with high levels associated with advanced disease stage and high-risk cytogenetics. HLA-E could serve as a new biomarker and treatment target for high-risk MM, while peptide P3 may be a potential treatment choice for targeting MM cells.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Hamed Bashiri, Hossein Tabatabaeian
Summary: Multiple myeloma, the second most prevalent hematologic malignancy, has seen increased survival rates due to novel drugs and combination therapies. However, drug resistance remains a significant issue, with autophagic activity playing a critical role. High mobility group box protein 1 (HMGB1)-dependent autophagy and proteasome suppression-induced autophagy have been found to contribute to drug resistance in multiple myeloma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Joanna Barankiewicz, Aleksander Salomon-Perzynski, Irena Misiewicz-Krzeminska, Ewa Lech-Maranda
Summary: Multiple myeloma is a common hematological malignancy that can have a recurrent clinical course. Immunomodulatory drugs have significantly improved the prognosis of patients with multiple myeloma. The use of the CRL4(CRBN) complex's activity for treating multiple myeloma is being explored further.
Review
Pathology
Hefei Ren, Sai Chen, Chang Liu, Hongkun Wu, Zhenhua Wang, Xiaomin Zhang, Jigang Ren, Lin Zhou
Summary: Circular RNAs (circRNAs) are RNA molecules with a stable closed-loop structure, playing important roles in transcriptional regulation and splicing. In Multiple Myeloma (MM), circRNAs may contribute to the development and progression as oncogenes or regulators, and their expression levels and molecular mechanism are closely related to the diagnosis, therapeutic sensitivity, and clinical prognosis of MM patients.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Oncology
Runjie Sun, Wei Liu, Yangang Zhao, Haoyu Chen, Zhenzhen Wang, Yanyu Zhang, Xiaoqi Sun, Xing Cui
Summary: This study investigated the role of exosomal circular RNAs (exo-circRNAs) in multiple myeloma (MM) related myocardial damage. Bioinformatics analysis revealed that upregulated circRNAs may promote MM-related myocardial damage. Cell experiments showed that the circ-G042080/hsa-miR-4268/TLR4 axis may exist in H9C2 cells and cause abnormal autophagy. Abnormal expression of serum exo-circRNAs was found to be associated with MM-related myocardial damage, suggesting their potential as diagnostic markers and therapeutic targets.
CANCER CELL INTERNATIONAL
(2021)
Article
Medicine, Research & Experimental
Antoine Domenger, Caroline Choisy, Ludivine Baron, Veronique Mayau, Emeline Perthame, Ludovic Deriano, Bertrand Arnulf, Jean-Christophe Bories, Gilles Dadaglio, Caroline Demangel
Summary: This study demonstrates the efficacy of the Sec61 inhibitor mycolactone for targeting multiple myeloma (MM) cells by disrupting protein translocation and inducing cell death. Combining mycolactone with bortezomib enhances cell death and overcomes acquired resistance to the proteasome inhibitor. This combination shows superior therapeutic efficacy in animal models without inducing toxic side effects.
EMBO MOLECULAR MEDICINE
(2022)
Article
Immunology
Hong Phuong Nguyen, Anh Quynh Le, Enze Liu, Annamaria Cesarano, Francesco DiMeo, Fabiana Perna, Reuben Kapur, Brian A. Walker, Ngoc Tung Tran
Summary: This study reveals that PRMT1 is highly expressed in MM and associated with poor prognosis, and targeting PRMT1 can inhibit MM cell growth and induce cell death. The PRMT1 inhibitor MS023 shows effectiveness in suppressing the viability of primary cells from newly diagnosed and relapsed/refractory patients. In addition, suppression of PRMT1 enhances T cell activation and attenuates MM tumor growth in vivo.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Sara Ovejero, Elena Viziteu, Laure Dutrieux, Julie Devin, Yea-Lih Lin, Elina Alaterre, Michel Jourdan, Jihane Basbous, Guilhem Requirand, Nicolas Robert, Hugues de Boussac, Anja Seckinger, Dirk Hose, Laure Vincent, Charles Herbaux, Angelos Constantinou, Philippe Pasero, Jerome Moreaux
Summary: High expression of BLM is associated with poor outcome in multiple myeloma patients. Inhibition of BLM, combined with the alkylating agent melphalan, can effectively inhibit cell growth and promote cell death, especially in melphalan-resistant patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jian Wu, Min Zhang, Omar Faruq, Eldad Zacksenhaus, Wenming Chen, Aijun Liu, Hong Chang
Summary: This study explores the role of SMAD1 in multiple myeloma (MM), identifying critical axes of MM drug resistance and proposing a potentially new therapeutic strategy to treat drug-resistant MM through targeted inhibition of SMAD1.
BIOMARKER RESEARCH
(2021)
Article
Hematology
Jill Corre, Nikhil C. Munshi, Herve Avet-Loiseau
Summary: Although therapeutic strategies for multiple myeloma patients have been adapted based on age and comorbidities, high-risk patients still lack efficient treatment options. There is an urgent need to revise the current definition of risk in order to provide more effective drug combinations for these patients.
Article
Oncology
Francesca Cottini, Jose Rodriguez, Tiffany Hughes, Nidhi Sharma, Ling Guo, Gerard Lozanski, Bei Liu, Emanuele Cocucci, Yiping Yang, Don Benson
Summary: CD56 signaling in multiple myeloma plays a critical role in promoting cell growth, survival, and adhesion by activating CREB1 target genes, MCL1 and BCL2. Inhibition of CREB1 alone or in combination with lenalidomide presents a potential synthetic lethal approach in CD56-expressing patients with multiple myeloma.
MOLECULAR CANCER RESEARCH
(2022)
Article
Cell Biology
Yanyu Zhang, Michael Pisano, Nianhu Li, Guoqing Tan, Fumou Sun, Yan Cheng, Yanyan Zhang, Xing Cui
Summary: The study identified an association between the abnormal expression of serum exosome-derived circRNA and MM-related peripheral neuropathy, suggesting a potential role of exo-circRNA as a novel therapeutic target for MM-related PN.
CELLULAR SIGNALLING
(2021)
Article
Medicine, Research & Experimental
A. G. M. Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Alexandra Achille, David Noyes, Gabriela Wright, Bin Fang, Victoria Izumi, John Koomen, Rupal Rampakrishnan, Tuan P. Nguyen, Gabriel De Avila, Ariosto S. Silva, Praneeth Sudalagunta, Rafael Renatino Canevarolo, Maria D. Coelho Siqueira Silva, Raghunandan Reddy Alugubelli, Hongyue A. Dai, Amit Kulkarni, William S. Dalton, Oliver A. Hampton, Eric A. Welsh, Jamie K. Teer, Alexandre Tungesvik, Kenneth L. Wright, Javier Pinilla-Ibarz, Eduardo M. Sotomayor, Kenneth H. Shain, Jason Brayer
Summary: The research suggests that HDAC11 plays a crucial role in multiple myeloma, with its absence leading to decreased plasma cells. Selective HDAC11 inhibitors and HDAC11 deficiency induce cell death in MM cells both in vitro and in vivo, indicating a potential therapeutic value.
Letter
Oncology
Chunyan Gu, Ting Lu, Wang Wang, Miaomiao Shao, Rongfang Wei, Mengjie Guo, Rui Li, Li Qiao, Ye Hu, Fenghuang Zhan, Anja Seckinger, Dirk Hose, Ye Yang
Review
Biochemistry & Molecular Biology
Xiaozhu Tang, Hongyan Ren, Mengjie Guo, Jinjun Qian, Ye Yang, Chunyan Gu
Summary: circRNAs are a class of interesting and conserved single-stranded RNA molecules that play important roles in various biological processes, especially in microRNA sponges, gene splicing and transcription regulation, RNA-binding protein sponges, and protein/peptide translation. They are involved in various human diseases, particularly cancers, and may serve as better predictive biomarkers and therapeutic targets for cancer treatment.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2021)
Article
Cell Biology
Renjie Dou, Jinjun Qian, Wei Wu, Yanxin Zhang, Yuxia Yuan, Mengjie Guo, Rongfang Wei, Shu Yang, Artur Jurczyszyn, Siegfried Janz, Meral Beksac, Chunyan Gu, Ye Yang
Summary: SRD5A1 downregulation simultaneously regulates both the apoptosis and the autophagic process in multiple myeloma, serving as a potential biomarker and target for disease progression and prognosis.
CELL DEATH & DISEASE
(2021)
Letter
Oncology
Fengjie Jiang, Xiaozhu Tang, Chao Tang, Zhen Hua, Mengying Ke, Chen Wang, Jiamin Zhao, Shengyao Gao, Artur Jurczyszyn, Siegfried Janz, Meral Beksac, Fenghuang Zhan, Chunyan Gu, Ye Yang
Summary: This study identified that HNRNPA2B1 is upregulated in multiple myeloma (MM) patients and negatively correlated with prognosis, playing a role in regulating cell proliferation by modulating AKT3 expression. This suggests that HNRNPA2B1 may act as a potential therapeutic target for MM through the ILF3-dependent pattern.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Cell Biology
Xuxing Shen, Chao Wu, Meng Lei, Qing Yan, Haoyang Zhang, Lina Zhang, Xueyuan Wang, Ye Yang, Jianyong Li, Yongqiang Zhu, Lijuan Chen
Summary: The novel proteasome inhibitor D395 showed high cytotoxicity to MM cells, with lower cardiotoxicity compared to carfilzomib. D395 demonstrated remarkable anti-MM activity and mild cardiotoxicity in both in vitro and in vivo experiments.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Mengjie Guo, Pinggang Ding, Zhen Zhu, Lu Fan, Yanyan Zhou, Shu Yang, Ye Yang, Chunyan Gu
Summary: The study showed that elevated RFWD2 expression in MM patients leads to adverse outcomes and drug resistance. RFWD2 is involved in controlling cell cycle, growth and death in MM biology. Targeting RFWD2 may be an effective strategy to inhibit cellular proliferation and overcome drug resistance in MM.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Ling Wang, Jinjun Qian, Ye Yang, Chunyan Gu
Summary: The SUMO system plays a crucial role in regulating protein stability and function, influencing cell cycle progression and drug resistance. It has the potential to serve as biomarkers and therapeutic targets in hematological malignancies.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan, Ye Yang
Summary: The study found that AHSA1 expression was increased in multiple myeloma samples, which was significantly associated with disease relapse and poor prognosis. Additionally, AHSA1 played a role in promoting MM cell proliferation and proteasome inhibitor (PI) resistance. Bufalin and KU-177, as selective inhibitors of AHSA1, may be promising targets for treating MM cell proliferation and proteasome inhibitor resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Zhen Hua, Rongfang Wei, Mengjie Guo, Zigen Lin, Xichao Yu, Xinying Li, Chunyan Gu, Ye Yang
Summary: This study highlights the role of the YTHDF2/STAT5A/MAP2K2/p-ERK axis in the proliferation of multiple myeloma (MM), and targeting YTHDF2 may be a promising therapeutic strategy.
Article
Pharmacology & Pharmacy
Rongfang Wei, Xing Cui, Jie Min, Zigen Lin, Yanyan Zhou, Mengjie Guo, Xiaojuan An, Hao Liu, Siegfried Janz, Chunyan Gu, Hongbo Wang, Ye Yang
Summary: This study found that NAT10 is significantly upregulated in multiple myeloma (MM) patients and is closely associated with poor prognosis. Enforced expression of NAT10 promotes MM growth, while its knockdown reverses these effects. Further investigation revealed CEP170 as an important downstream target of NAT10. These findings suggest that NAT10 may serve as a promising therapeutic target in MM.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Oncology
Yuanjiao Zhang, Xichao Yu, Rongze Sun, Jie Min, Xiaozhu Tang, Zigen Lin, Siyuan Xie, Xinying Li, Shengfeng Lu, Zhidan Tian, Chunyan Gu, Lesheng Teng, Ye Yang
Summary: This study found that SFRS8 is upregulated in multiple myeloma and is associated with poor prognosis. SFRS8 can promote the progression of myeloma by regulating the alternative splicing of CACYBP and promote osteoclast differentiation through exosomes. Targeting the SFRS8/CACYBP/beta-catenin axis may be a promising strategy for the diagnosis and treatment of multiple myeloma.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Xiaozhu Tang, Zhendong Deng, Pinggang Ding, Wanting Qiang, Yue Lu, Shengyao Gao, Ye Hu, Ye Yang, Juan Du, Chunyan Gu
Summary: The study reveals that circHNRNPU_603aa has potential diagnostic and therapeutic value in multiple myeloma.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Hongbo Wang, Qinghai Meng, Jinjun Qian, Muxi Li, Chunyan Gu, Ye Yang
Summary: This review provides an overview of different types of RNAs in cancer diagnostics and treatment, discussing their unique characteristics and potential applications. It highlights the increasing use of mRNAs, lncRNAs, circRNAs, and miRNAs as diagnostic markers or therapeutic targets in various cancers. The review also explores the mechanisms by which these RNAs regulate and participate in cancer development, as well as their potential in cancer prediction and treatment.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Rongfang Wei, Yan Zhu, Yuanjiao Zhang, Wene Zhao, Xichao Yu, Ling Wang, Chunyan Gu, Xiaosong Gu, Ye Yang
Summary: In patients with multiple myeloma (MM), increased expression of AIMP1 is closely associated with unfavorable prognostic outcomes. AIMP1 promotes MM cell proliferation by activating the MAPK signaling pathway and affects bone lesion formation through histone acetylation. Additionally, AIMP1 plays a role in promoting osteoclast differentiation.
CANCER COMMUNICATIONS
(2022)
Review
Oncology
Yiwen Zhang, Lu Lu, Feifeng Song, Xiaozhou Zou, Yujia Liu, Xiaowei Zheng, Jinjun Qian, Chunyan Gu, Ping Huang, Ye Yang
Summary: Non-protein target drugs, especially RNA-based gene therapies, have gained global recognition for treating hereditary diseases. However, there is a lack of miracle drugs for cancer, which remains a challenging condition. As biopharmaceutical research advances, the focus of cancer therapy has shifted towards non-protein targets, particularly RNA therapeutics such as oligonucleotide drugs and mRNA vaccines. This review provides a summary of the clinical research progress in RNA therapeutics, emphasizing the importance of appropriate target selection and optimized delivery vehicles in enhancing the effectiveness of cancer treatment in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
